Sumitomo Pharma Co., Ltd. (DNPUF)
OTCMKTS
· Delayed Price · Currency is USD
6.53
+0.73 (12.59%)
At close: May 2, 2025
Sumitomo Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 398,832 | 314,558 | 555,544 | 560,035 | 515,952 | Upgrade
|
| Revenue Growth (YoY) | 26.79% | -43.38% | -0.80% | 8.54% | 6.88% | Upgrade
|
| Cost of Revenue | 153,437 | 126,577 | 178,919 | 157,127 | 137,773 | Upgrade
|
| Gross Profit | 245,395 | 187,981 | 376,625 | 402,908 | 378,179 | Upgrade
|
| Selling, General & Admin | 180,605 | 397,705 | 339,212 | 217,339 | 173,666 | Upgrade
|
| Research & Development | 49,865 | 112,637 | 131,858 | 94,903 | 132,682 | Upgrade
|
| Other Operating Expenses | 1,902 | 942 | -2,200 | -1,043 | 825 | Upgrade
|
| Operating Expenses | 232,372 | 543,117 | 502,974 | 342,941 | 323,880 | Upgrade
|
| Operating Income | 13,023 | -355,136 | -126,349 | 59,967 | 54,299 | Upgrade
|
| Interest Expense | -13,500 | -3,893 | -2,640 | -2,970 | -2,436 | Upgrade
|
| Interest & Investment Income | 2,307 | 2,839 | 5,486 | 1,175 | 1,153 | Upgrade
|
| Earnings From Equity Investments | -905 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 32,829 | 26,308 | 24,530 | 8,037 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -30 | -95 | -8 | -127 | Upgrade
|
| EBT Excluding Unusual Items | 925 | -323,391 | -97,290 | 82,694 | 60,926 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -224 | 24,735 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 16,686 | 501 | 24,635 | 267 | 16,925 | Upgrade
|
| Pretax Income | 17,611 | -323,114 | -47,920 | 82,961 | 77,851 | Upgrade
|
| Income Tax Expense | -6,024 | -8,185 | 48,794 | 42,361 | 41,022 | Upgrade
|
| Earnings From Continuing Operations | 23,635 | -314,929 | -96,714 | 40,600 | 36,829 | Upgrade
|
| Minority Interest in Earnings | -1 | -40 | 22,202 | 15,813 | 19,390 | Upgrade
|
| Net Income | 23,634 | -314,969 | -74,512 | 56,413 | 56,219 | Upgrade
|
| Net Income to Common | 23,634 | -314,969 | -74,512 | 56,413 | 56,219 | Upgrade
|
| Net Income Growth | - | - | - | 0.34% | 37.95% | Upgrade
|
| Shares Outstanding (Basic) | 397 | 397 | 397 | 397 | 397 | Upgrade
|
| Shares Outstanding (Diluted) | 397 | 397 | 397 | 397 | 397 | Upgrade
|
| EPS (Basic) | 59.49 | -792.79 | -187.55 | 141.99 | 141.50 | Upgrade
|
| EPS (Diluted) | 59.49 | -792.79 | -187.55 | 141.99 | 141.50 | Upgrade
|
| EPS Growth | - | - | - | 0.34% | 37.95% | Upgrade
|
| Free Cash Flow | 8,002 | -252,664 | 3,470 | 23,892 | 129,553 | Upgrade
|
| Free Cash Flow Per Share | 20.14 | -635.97 | 8.73 | 60.14 | 326.09 | Upgrade
|
| Dividend Per Share | - | - | 21.000 | 28.000 | 28.000 | Upgrade
|
| Dividend Growth | - | - | -25.00% | - | - | Upgrade
|
| Gross Margin | 61.53% | 59.76% | 67.79% | 71.94% | 73.30% | Upgrade
|
| Operating Margin | 3.26% | -112.90% | -22.74% | 10.71% | 10.52% | Upgrade
|
| Profit Margin | 5.93% | -100.13% | -13.41% | 10.07% | 10.90% | Upgrade
|
| Free Cash Flow Margin | 2.01% | -80.32% | 0.63% | 4.27% | 25.11% | Upgrade
|
| EBITDA | 38,585 | -317,371 | -85,086 | 98,315 | 76,972 | Upgrade
|
| EBITDA Margin | 9.67% | -100.89% | -15.32% | 17.55% | 14.92% | Upgrade
|
| D&A For EBITDA | 25,562 | 37,765 | 41,263 | 38,348 | 22,673 | Upgrade
|
| EBIT | 13,023 | -355,136 | -126,349 | 59,967 | 54,299 | Upgrade
|
| EBIT Margin | 3.26% | -112.90% | -22.74% | 10.71% | 10.52% | Upgrade
|
| Effective Tax Rate | - | - | - | 51.06% | 52.69% | Upgrade
|
| Advertising Expenses | - | 42,372 | 59,857 | 37,780 | 37,362 | Upgrade
|
Updated Jan 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.